Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Avalyn Pharma Inc.AVLN · Entity 4662 | Director | April 29, 2026 | May 01, 2026 |
| Climb Bio, Inc.ELYM · Entity 5064 | COO & CFO | October 31, 2022 | November 02, 2022 |
| Jade Biosciences, Inc.JBIO · Entity 4757 | Director | June 09, 2026 | June 11, 2026 |
| Neurogene Inc.NLTX · Entity 5160 | Director | June 08, 2023 | June 09, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Avalyn Pharma Inc.
Report date April 29, 2026 · Filed May 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.00 · Expires 2036-04-28 | Direct | 26,978 |
Reported balance
After 2026-04-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-30 · Grant · Acquired 26,978 · Balance 26,978 F1: 25% of the shares underlying this option vest and become exercisable on September 12, 2025, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares underlying this option vest and become exercisable on September 12, 2025, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
Climb Bio, Inc.
Report date October 31, 2022 · Filed November 02, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.27 · Expires 2032-10-30 | Direct | 170,000 |
Reported balance
After 2022-10-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-10-31 · Grant · Acquired 170,000 · Balance 170,000 F1: The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of October 31, 2022 (the "2022 Vesting Commencement Date") for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the 2022 Vesting Commencement Date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of October 31, 2022 (the "2022 Vesting Commencement Date") for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the 2022 Vesting Commencement Date.
Jade Biosciences, Inc.
Report date June 09, 2026 · Filed June 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.22 · Expires 2036-06-08 | Direct | 34,843 |
Reported balance
After 2026-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-09 · Grant · Acquired 34,843 · Balance 34,843 F1: This option represents a right to purchase shares of the Issuer's common stock, which vests in full on the earlier of (i) June 9, 2027 or (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continued service to the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: This option represents a right to purchase shares of the Issuer's common stock, which vests in full on the earlier of (i) June 9, 2027 or (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continued service to the Issuer.
Neurogene Inc.
Report date June 08, 2023 · Filed June 09, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.79 · Expires 2033-06-07 | Direct | 25,000 |
Reported balance
After 2023-06-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-08 · Grant · Acquired 25,000 · Balance 25,000 F1: The option vests as to 1/12 of the total shares monthly beginning July 8, 2023 until the option is fully vested on June 8, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests as to 1/12 of the total shares monthly beginning July 8, 2023 until the option is fully vested on June 8, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ALDER BIOPHARMACEUTICALS INC
Report date October 22, 2019 · Filed October 24, 2019
Section 16 reporting ended · disclosed 2019-10-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2019-10-22 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2019-10-22 · Grant · Acquired 11,684 · Balance 16,092 F1: On August 13, 2018, the Reporting Person was granted restricted stock units which represented a contingent right to receive a maximum of 17,526 shares of Issuer's Common Stock ("RSU"), of which 5,842 shares had vested and the remaining 11,684 shares were to vest upon the achievement of one or more milestones or a change of control of the Issuer. The remaining shares subject to the RSU vested in full upon the Effective Time (as such term is defined in footnote 4). Row 2 · 2019-10-22 · Other · Disposed 16,092 · Balance 0 F2: On September 16, 2019, the Reporting Person entered into a Tender and Support (the "Support Agreement") with H. Lundbeck A/S ("Lundbeck"), Lundbeck LLC, Violet Acquisition Corp., a wholly owned subsidiary of Lundbeck ("Purchaser") and certain other securityholders of Issuer, pursuant to which the Reporting Person agreed to tender all shares of the Issuer's Common Stock, Class A-1 Convertible Preferred Stock or shares of Common Stock underlying stock options, as the case may be, held by Reporting Person to Purchaser (the "Tender Offer"). On October 22, 2019, Purchaser accepted the Tender Offer. F3: The Reporting Person will also receive one non-transferable contingent value right for each share held, which will entitle them to receive up to an additional $2.00 per share upon achievement of a milestone. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.55 · Expires 2028-04-15 | Direct | 0 |
Reported balance
After 2019-10-22 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-10-22 · Disposition to issuer · Disposed 300,000 · Balance 0 F4: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Lundbeck, Lundbeck LLC and Purchaser. On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck. F5: The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of April 16, 2018 (the "2018 Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the 2018 Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the 2018 Vesting Commencement Date. F6: The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive both (i) a cash payment equal to (A) the excess, if any of (x) $18.00 over (y) the Exercise Price per share listed in Column 2 of Table II of this Form 4, multiplied by (B) the total number of shares listed in Column 5 of Table II of this Form 4, and (ii) one non-transferable contingent value right for each share subject to this option, which represents the contractual right to receive up to an additional $2.00 per share upon achievement of a milestone. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.00 · Expires 2029-02-05 | Direct | 0 |
Reported balance
After 2019-10-22 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-10-22 · Disposition to issuer · Disposed 150,000 · Balance 0 F4: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Lundbeck, Lundbeck LLC and Purchaser. On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck. F6: The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive both (i) a cash payment equal to (A) the excess, if any of (x) $18.00 over (y) the Exercise Price per share listed in Column 2 of Table II of this Form 4, multiplied by (B) the total number of shares listed in Column 5 of Table II of this Form 4, and (ii) one non-transferable contingent value right for each share subject to this option, which represents the contractual right to receive up to an additional $2.00 per share upon achievement of a milestone. F7: The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of January 1, 2019 (the "2019 Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the 2019 Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the 2019 Vesting Commencement Date. |
Filing footnotes · ownership attribution and instrument terms
F1: On August 13, 2018, the Reporting Person was granted restricted stock units which represented a contingent right to receive a maximum of 17,526 shares of Issuer's Common Stock ("RSU"), of which 5,842 shares had vested and the remaining 11,684 shares were to vest upon the achievement of one or more milestones or a change of control of the Issuer. The remaining shares subject to the RSU vested in full upon the Effective Time (as such term is defined in footnote 4).
F2: On September 16, 2019, the Reporting Person entered into a Tender and Support (the "Support Agreement") with H. Lundbeck A/S ("Lundbeck"), Lundbeck LLC, Violet Acquisition Corp., a wholly owned subsidiary of Lundbeck ("Purchaser") and certain other securityholders of Issuer, pursuant to which the Reporting Person agreed to tender all shares of the Issuer's Common Stock, Class A-1 Convertible Preferred Stock or shares of Common Stock underlying stock options, as the case may be, held by Reporting Person to Purchaser (the "Tender Offer"). On October 22, 2019, Purchaser accepted the Tender Offer.
F3: The Reporting Person will also receive one non-transferable contingent value right for each share held, which will entitle them to receive up to an additional $2.00 per share upon achievement of a milestone.
F4: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Lundbeck, Lundbeck LLC and Purchaser. On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck.
F5: The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of April 16, 2018 (the "2018 Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the 2018 Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the 2018 Vesting Commencement Date.
F6: The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive both (i) a cash payment equal to (A) the excess, if any of (x) $18.00 over (y) the Exercise Price per share listed in Column 2 of Table II of this Form 4, multiplied by (B) the total number of shares listed in Column 5 of Table II of this Form 4, and (ii) one non-transferable contingent value right for each share subject to this option, which represents the contractual right to receive up to an additional $2.00 per share upon achievement of a milestone.
F7: The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of January 1, 2019 (the "2019 Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the 2019 Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the 2019 Vesting Commencement Date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 09, 2026 Filed Jun 11, 2026 20:37 UTC | Jade Biosciences, Inc. JBIO · Entity 4757 | GrantStock Option (Right to Buy) · Derivative | 34,843 | $0.00 Strike: $15.22 | $0.00 |
DisclosureSEC source: 0001193125-26-267708 · ownership.xml · derivative · entry 1 Lavelle Erin · CIK 0001737613 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,843 Underlying: Common Stock · 34,843 shares Expires 2036-06-08 F1 · derivative.exercise_date: This option represents a right to purchase shares of the Issuer's common stock, which vests in full on the earlier of (i) June 9, 2027 or (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| April 30, 2026 Filed May 1, 2026 22:26 UTC | Avalyn Pharma Inc. AVLN · Entity 4662 | GrantStock Option (Right to Buy) · Derivative | 26,978 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001193125-26-201860 · ownership.xml · derivative · entry 1 Lavelle Erin · CIK 0001737613 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,978 Underlying: Common Stock · 26,978 shares Expires 2036-04-28 F1 · derivative.exercise_date: 25% of the shares underlying this option vest and become exercisable on September 12, 2025, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| April 29, 2025 Filed May 1, 2025 22:15 UTC | Jade Biosciences, Inc. JBIO · Entity 4757 | GrantStock Option (Right to Buy) · Derivative | 23,017 | $0.00 Strike: $10.14 | $0.00 |
DisclosureSEC source: 0000950170-25-062119 · ownership.xml · derivative · entry 1 Lavelle Erin · CIK 0001737613 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,017 Underlying: Common Stock · 23,017 shares Expires 2035-04-29 F1 · derivative.exercise_date: This option represents a right to purchase 23,017 shares of the Issuer's common stock, which vests in full on the earlier of (i) April 29, 2026 or (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the recipient's continued service to the Issuer. Read SEC document |
| June 08, 2023 Filed Jun 9, 2023 20:25 UTC | Neurogene Inc. NLTX · Entity 5160 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $0.79 | $0.00 |
DisclosureSEC source: 0001209191-23-035857 · doc4.xml · derivative · entry 1 Lavelle Erin · CIK 0001737613 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2033-06-07 F1 · derivative.exercise_date: The option vests as to 1/12 of the total shares monthly beginning July 8, 2023 until the option is fully vested on June 8, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| October 31, 2022 Filed Nov 2, 2022 23:08 UTC | Climb Bio, Inc. ELYM · Entity 5064 | GrantStock Option (Right to Buy) · Derivative | 170,000 | $0.00 Strike: $3.27 | $0.00 |
DisclosureSEC source: 0001209191-22-055404 · doc4.xml · derivative · entry 1 Lavelle Erin · CIK 0001737613 · COO & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,000 Underlying: Common Stock · 170,000 shares Expires 2032-10-30 F1 · derivative.exercise_date: The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of October 31, 2022 (the "2022 Vesting Commencement Date") for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the 2022 Vesting Commencement Date. Read SEC document |
| May 12, 2022 Filed May 16, 2022 22:23 UTC | Neurogene Inc. NLTX · Entity 5160 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $1.07 | $0.00 |
DisclosureSEC source: 0001209191-22-029323 · doc4.xml · derivative · entry 1 Lavelle Erin · CIK 0001737613 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-05-11 F1 · derivative.exercise_date: The option vests as to 1/12 of the total shares monthly beginning June 12, 2022 until the option is fully vested on May 12, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 27, 2022 Filed Jan 31, 2022 22:16 UTC | Climb Bio, Inc. ELYM · Entity 5064 | GrantStock Option (Right to Buy) · Derivative | 170,000 | $0.00 Strike: $8.21 | $0.00 |
DisclosureSEC source: 0001209191-22-005659 · doc4.xml · derivative · entry 1 Lavelle Erin · CIK 0001737613 · COO & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,000 Underlying: Common Stock · 170,000 shares Expires 2032-01-26 F1 · derivative.exercise_date: For so long as the Reporting Person continuously provides services to the Issuer, this option will vest with respect to the shares as follows: 1/48th of the shares will vest on each monthly anniversary of January 27, 2022. Read SEC document |
| October 22, 2019 Filed Oct 24, 2019 23:12 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | Disposition to issuerStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $14.00 | $0.00 |
DisclosureSEC source: 0001209191-19-053922 · doc4.xml · derivative · entry 4 Lavelle Erin · CIK 0001737613 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 150,000 shares Expires 2029-02-05 F4 · date: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Lundbeck, Lundbeck LLC and Purchaser. On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck. F6 · derivative.exercise_date: The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive both (i) a cash payment equal to (A) the excess, if any of (x) $18.00 over (y) the Exercise Price per share listed in Column 2 of Table II of this Form 4, multiplied by (B) the total number of shares listed in Column 5 of Table II of this Form 4, and (ii) one non-transferable contingent value right for each share subject to this option, which represents the contractual right to receive up to an additional $2.00 per share upon achievement of a milestone. F7 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of January 1, 2019 (the "2019 Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the 2019 Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the 2019 Vesting Commencement Date. Read SEC document |
| October 22, 2019 Filed Oct 24, 2019 23:12 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | Disposition to issuerStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $14.55 | $0.00 |
DisclosureSEC source: 0001209191-19-053922 · doc4.xml · derivative · entry 3 Lavelle Erin · CIK 0001737613 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 300,000 shares Expires 2028-04-15 F4 · date: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Lundbeck, Lundbeck LLC and Purchaser. On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck. F5 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of April 16, 2018 (the "2018 Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the 2018 Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the 2018 Vesting Commencement Date. F6 · derivative.exercise_date: The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive both (i) a cash payment equal to (A) the excess, if any of (x) $18.00 over (y) the Exercise Price per share listed in Column 2 of Table II of this Form 4, multiplied by (B) the total number of shares listed in Column 5 of Table II of this Form 4, and (ii) one non-transferable contingent value right for each share subject to this option, which represents the contractual right to receive up to an additional $2.00 per share upon achievement of a milestone. Read SEC document |
| October 22, 2019 Filed Oct 24, 2019 23:12 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | OtherCommon Stock | 16,092 | $18.00 | $289,656.00 |
DisclosureSEC source: 0001209191-19-053922 · doc4.xml · nonDerivative · entry 2 Lavelle Erin · CIK 0001737613 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · date: On September 16, 2019, the Reporting Person entered into a Tender and Support (the "Support Agreement") with H. Lundbeck A/S ("Lundbeck"), Lundbeck LLC, Violet Acquisition Corp., a wholly owned subsidiary of Lundbeck ("Purchaser") and certain other securityholders of Issuer, pursuant to which the Reporting Person agreed to tender all shares of the Issuer's Common Stock, Class A-1 Convertible Preferred Stock or shares of Common Stock underlying stock options, as the case may be, held by Reporting Person to Purchaser (the "Tender Offer"). On October 22, 2019, Purchaser accepted the Tender Offer. F3 · price: The Reporting Person will also receive one non-transferable contingent value right for each share held, which will entitle them to receive up to an additional $2.00 per share upon achievement of a milestone. Read SEC document |
| October 22, 2019 Filed Oct 24, 2019 23:12 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | GrantCommon Stock | 11,684 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-053922 · doc4.xml · nonDerivative · entry 1 Lavelle Erin · CIK 0001737613 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,092 F1 · shares: On August 13, 2018, the Reporting Person was granted restricted stock units which represented a contingent right to receive a maximum of 17,526 shares of Issuer's Common Stock ("RSU"), of which 5,842 shares had vested and the remaining 11,684 shares were to vest upon the achievement of one or more milestones or a change of control of the Issuer. The remaining shares subject to the RSU vested in full upon the Effective Time (as such term is defined in footnote 4). Read SEC document |
| April 25, 2019 Filed Apr 25, 2019 22:49 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | SaleCommon Stock | 1,434 | $13.67 | $19,599.34 |
DisclosureSEC source: 0001209191-19-026034 · doc4.xml · nonDerivative · entry 2 Lavelle Erin · CIK 0001737613 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,408 F2 · shares: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the RSU. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.6676 to $13.67, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 3 to this Form 4. Read SEC document |
| April 23, 2019 Filed Apr 25, 2019 22:49 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | GrantCommon Stock | 5,842 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-026034 · doc4.xml · nonDerivative · entry 1 Lavelle Erin · CIK 0001737613 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,842 F1 · security: On August 13, 2018, the Reporting Person was granted restricted stock units which represented a contingent right to receive a maximum of 17,526 shares of Issuer's Common Stock (the "RSU"). Up to 5,842 shares subject to the RSU vest upon obtaining acceptance by the U.S. Food and Drug Administration (or any successor entity thereto) (the "FDA") of the first Biologics License Application submitted to the FDA by the Company or an affiliate seeking approval for the commercial sale and marketing of eptinezumab in the United States for review and certification by the Issuer's Compensation Committee that the achievement of such milestone had been achieved (the "FDA Filing Milestone") and the remaining shares subject to the RSU vest upon certain other performance criteria. On April 23, 2019, the Issuer's Compensation Committee certified that the FDA Milestone had been achieved, resulting in the vesting of 5,842 shares subject to the RSU. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 21:51 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $14.00 | $0.00 |
DisclosureSEC source: 0001209191-19-008591 · doc4.xml · derivative · entry 1 Lavelle Erin · CIK 0001737613 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2029-02-05 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of January 1, 2019 (the "Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the Vesting Commencement Date. Read SEC document |
| April 16, 2018 Filed Apr 18, 2018 21:10 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | GrantStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $14.55 | $0.00 |
DisclosureSEC source: 0001209191-18-025410 · doc4.xml · derivative · entry 1 Lavelle Erin · CIK 0001737613 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2028-04-15 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of April 16, 2018 (the "Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the Vesting Commencement Date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.